endpts.com·Apr 30, 2026
A Congressional spending committee is advocating for the FDA to prohibit the use of clinical trial data from China in future drug applications by pharmaceutical companies.
A significant development for professionals in the healthtech and biotech sectors is the Congressional move to potentially ban the use of clinical trial data from China in FDA drug trial applications. This could have substantial implications for drugmakers relying on Chinese data, affecting strategies for clinical trials and regulatory submissions. It is crucial for stakeholders to closely monitor this legislative action and consider diversifying data sources to mitigate risks associated with regulatory changes.